Topic

Michael Christel is the group managing editor of 

Pharmaceutical Executive, Pharmaceutical Commerce

 and can be reached at mchristel@mjhlifesciences.com.

Articles

Tapping the potential of new market mindset in insomnia—delivering a quality next day.

A Sleeping Giant?: Quviviq 

’s 2022 summer editorial intern and is now an Assistant Editor for 

Dual-targeted injection poised to rock GLP-1 field in diabetes—and eventually weight loss.

Next-level Efficacy: Mounjaro

Lisa Henderson is the group editorial director of 

 and can be reached at lhenderson@mjhlifesciences.com.

More favorable administration, reimbursement could separate latest PCSK9 entrant.

LDL Game Changer: Leqvio

CEO, Chairman, and Founder, NeuBase Therapeutics

Failed efforts do not overshadow field’s progress, resolve.

The Silver Lining Of Innovation in Genetic Medicine

Innovative and continuous remote patient monitoring, along with AI-based predictive analytics, are advancing progress toward replacing the one-size-fits-all, population-driven vaccination model.

Getting ‘Personal’ With Vaccine Development

 and can be reached at mhollan@mjhlifesciences.com.

The road to precision medicine as a fixture in healthcare delivery is still a journey, but recent advances and new understandings in gene profiling, biomarker development, and AI and data analytics are steadily bringing these therapies closer to the individual patient every day.

Milestones and Momentum: Assessing Advancements in Personalized Medicine 

Pharma companies may benefit from meeting challenges and embracing small molecule drug discovery.

Embracing the Renaissance of Small Molecule Drug Discovery

Dr. Kyle Flanigan, Ph.D., discusses the benefits of an oral COVID-19 vaccine.

Q&A with Dr. Kyle Flanigan, Ph.D., Co-Founder and CEO of USSF

Has data science finally reached a level playing field with all of the science data being uncovered in the make, test, decide innovation cycle?

Has Data Science Caught up with Science Data: Q&A with Mike McKee, President of Dotmatics

Kobel discusses taking a company public during a challenging time in the market.

R&D/Clinical Trials